Hologic (NASDAQ:HOLX) Issues FY25 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its FY25 earnings guidance on Monday morning. The company provided EPS guidance of $4.25-4.35 for the period, compared to the consensus EPS estimate of $4.33. The company issued revenue guidance of $4.15-4.20 billion, compared to the consensus revenue estimate of $4.21 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Price Performance

Shares of Hologic stock traded up $1.39 on Monday, hitting $83.72. 3,241,693 shares of the company traded hands, compared to its average volume of 1,582,480. The firm’s 50-day simple moving average is $80.99 and its 200 day simple moving average is $78.02. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The company has a market cap of $19.45 billion, a P/E ratio of 28.48, a P/E/G ratio of 2.93 and a beta of 0.98. Hologic has a 12-month low of $66.93 and a 12-month high of $84.67.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HOLX. StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Stephens reaffirmed an “overweight” rating and set a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Mizuho lifted their target price on shares of Hologic from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and cut their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, Leerink Partners cut their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.50.

Insiders Place Their Bets

In other Hologic news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.